OSBPL7-IN-1|cas:1269826-44-9|西域试剂

OSBPL7-IN-1,99.79%

产品编号：Bellancom-143200| CAS NO：1269826-44-9| 分子式：C₂₀H₁₉Cl₂F₃N₂O₃| 分子量：463.28

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-143200	￥3000.00	杭州北京（现货）
Bellancom-143200	￥4800.00	杭州北京（现货）
Bellancom-143200	￥9500.00	杭州北京（现货）
Bellancom-143200	￥12500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

OSBPL7-IN-1

产品介绍

OSBPL7-IN-1 是一种具有口服活性的氧甾醇结合蛋白样 7 (OSBPL7) 抑制剂。OSBPL7-IN-1 促进质膜上 ABCA1 的增加而不影响 mRNA 表达。

生物活性

OSBPL7-IN-1 is an orally active oxysterol binding protein like 7 (OSBPL7) inhibitor. OSBPL7-IN-1 promotes an increase of ABCA1 at the plasma membrane without affecting mRNA expression.

体外研究

OSBPL7-IN-1 (compound G or Cpd G; 1-10 µM) increase plasma membrane ATP-binding cassette transporter (ABCA1) in cultured human podocytes, and significantly increase ABCA1-dependent cholesterol efflux.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice induced by Adriamycin (ADR)
Dosage:	100 mg/kg
Administration:	Oral gavage; daily; for 28 days
Result:	Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.

体内研究

OSBPL7-IN-1 (100 mg/kg; oral gavage; daily; for 28 days) treatment normalizes proteinuria and prevents renal function decline in mouse models of proteinuric kidney disease.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female Balb/c mice induced by Adriamycin (ADR)
Dosage:	100 mg/kg
Administration:	Oral gavage; daily; for 28 days
Result:	Normalized proteinuria, and significantly reduced renal fibrosis and renal functional decline.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (269.82 mM; ultrasonic and warming and heat to 60°C)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.1585 mL	10.7926 mL	21.5852 mL
5 mM	0.4317 mL	2.1585 mL	4.3170 mL
10 mM	0.2159 mL	1.0793 mL	2.1585 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (4.49 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (4.49 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。